Device Trial Radar · NCT07287436
Elite AF IDE Trial (Elite AF)
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Sep 18, 2026
Primary completion
Jan 2028
Study completion Nov 2032
Sponsor
- Lead sponsor
- Boston Scientific CorporationPublic (BSX)
- Sponsor type
- Industry
- First posted
- Dec 17, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to establish the safety and effectiveness of the WATCHMAN Elite Left Atrial Appendage Closure (LAAC) Device for subjects with non-valvular atrial fibrillation who are eligible for anticoagulation therapy to reduce the risk of stroke.
Conditions
- Atrial Fibrillation (AF)
- Stroke
Interventions
WATCHMAN Elite LAAC DeviceDevice
WATCHMAN Elite LAAC Device Implantation
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary effectiveness endpoint is the rate of effective LAA closure.Time frame: 45 days
1 more outcomes with a free account
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Arrhythmia Research Group
Jonesboro, Arkansas · Recruiting
4 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.